In COVID-19 clinical update #120, Dr. Griffin discusses outcomes of SARS-CoV-2 reinfection, CDC recommendation for vaccines in young children, neurodevelopment outcomes in infants of mothers testing positive for COVID during pregnancy, efficacy of monoclonal antibodies and antivirals in hamsters, rebound phenomenon after PAXLOVID in high-risk persons, hospitalization for infection after PAXLOVID treatment, and risk of long COVID with different variants.
TWiV provides an update on hepatitis of unknown etiology in children, an experimental nanoparticle vaccine for Epstein-Barr virus, and minimal impact of bamlanivimab therapy on antiviral antibodies induced by vaccination.
In COVID-19 clinical update #119, Dr. Griffin reviews tixagevimab for infection prevention, ivermectin for outpatient infection treatment, symptom rebound after PAXLOVID treatment, bamlanivimab minimally impacting immune response to vaccination, in-hospital mortality among infection patients, residual viral antigen in patients following infection, usage of Casirvimab/Imdevimab and Remdesivir in infected patients with depleted B-cells, and rheumatic symptoms following infection.
TWiV discusses the situation with monkeypox, risk factors for SARS-CoV-2 infections of cats and dogs, and a lineage-tracing mouse model for studying papillomavirus infections.
TWiV reviews human monkeypox infections, evidence for human Mimivrus infections, and incidence of long COVID in post-vaccine SARS-CoV-2 infections.
In COVID-19 clinical update #117, Dr. Griffin discusses duration of virus shedding, association between pre-exposure to steroids and infection outcome, post-infection subtypes, rehabilitation for post-acute infection, Tixagevimab/Cilgavimab for infection prevention, antibody prophylaxis and vaccination in kidney transplant recipients, remdesivir and bebtelovimab fact sheets for providers, the updated guidelines on treatment with Famotidine, Paxlovid rebound symptom characterizations, antigen test positivity duration, viral dynamics of variants and isolation, association of inflammation in CS fluid, and transmission dynamics in Ghana.
Vincent travels to Cold Spring Harbor Laboratory to speak with David Baltimore, John Coffin, and Harold Varmus about the discovery in 1970 of retroviral reverse transcriptase and its impact on life sciences research.
In COVID-19 clinical update #115, Dr. Griffin discusses croup association with infection surge, rhinovirus co-circulation in children, shedding following vaccination, high vaccine efficacy in children 6 mo-5 yr, vaccine protection for hospitalized patients, convalescent plasma as post-exposure prophylaxis, real-world effectiveness of PAXLOVID, effectiveness of PAXLOVID in reducing hospitalization, infection rebound after PAXLOVID, relapse of symptomatic infection after PAXLOVID, remdesivir and bebtelovimab fact sheets for providers, guidelines on usage of anticoagulation drugs, long covid symptoms after vaccination, excess mortality in MA, infection sequelae and immunity, and post infection conditions among adults.
In this special episode, Dr. Griffin answers questions about the recent cases of monkeypox including their origin, clinical presentation, diagnosis, treatment, and overall risk.
TWiV reviews recent cases of monkeypox, presence of SARS-CoV-2 RNA but not infectious virus in feces, and the association of autoantibodies to interferons with severe COVID-19.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Brianne Barker, Ph.D.
Rich Condit, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.
Kathy Spindler, Ph.D.